CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s Why

CureVac (NASDAQ:CVAC) gapped up before the market opened on Friday . The stock had previously closed at $3.26, but opened at $3.37. CureVac shares last traded at $3.35, with a volume of 42,511 shares trading hands.

Wall Street Analyst Weigh In

Separately, JMP Securities reissued a “market outperform” rating and issued a $16.00 target price on shares of CureVac in a research note on Friday, February 14th.

CureVac Stock Performance

The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The stock has a 50-day moving average of $3.04 and a 200 day moving average of $3.17. The stock has a market cap of $724.61 million, a PE ratio of 5.87 and a beta of 2.48.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The firm had revenue of $15.44 million during the quarter, compared to analysts’ expectations of $6.40 million. Equities analysts predict that CureVac will post 0.72 EPS for the current fiscal year.

Institutional Trading of CureVac

Several hedge funds have recently made changes to their positions in the company. Two Sigma Advisers LP purchased a new stake in shares of CureVac during the 4th quarter valued at approximately $48,000. Jump Financial LLC purchased a new stake in CureVac in the fourth quarter valued at $55,000. D. E. Shaw & Co. Inc. purchased a new stake in CureVac in the fourth quarter valued at $66,000. Barclays PLC acquired a new position in shares of CureVac in the 3rd quarter valued at $67,000. Finally, XTX Topco Ltd grew its holdings in shares of CureVac by 90.2% during the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company’s stock worth $83,000 after purchasing an additional 11,553 shares during the period. Hedge funds and other institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.